Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
News about Merit Medical Systems, Inc. (NASDAQ: MMSI) focuses on its role as a healthcare technology and medical device company engaged in the development, manufacture, and distribution of proprietary devices for interventional, diagnostic, and therapeutic procedures. Company announcements highlight activity in cardiology, radiology, oncology, critical care, and endoscopy, as well as updates on its Cardiovascular and Endoscopy segments.
Investors and healthcare professionals following MMSI news will see earnings releases, financial guidance updates, and segment performance details reported through quarterly results and Form 8-K filings. These updates often include net sales by segment, constant currency revenue figures, and non-GAAP financial measures, along with management commentary on operating performance and outlook.
Merit’s news flow also features product and clinical milestones. The company has issued releases on the WRAPSODY Cell-Impermeable Endoprosthesis (CIE), including regulatory approvals, commercialization strategies, and 24‑month efficacy results from the WAVE trial and related registries in hemodialysis patients. Additional coverage includes updates on the SCOUT Radar Localization system in breast cancer care and milestones in its global utilization.
Another key theme in MMSI news is portfolio expansion through acquisitions. Merit has announced transactions such as the asset purchase agreement to acquire the C2 CryoBalloon device and related technology for gastrointestinal disorders and has reported the closing of this acquisition in subsequent filings. These items provide insight into how the company is broadening its Endoscopy portfolio and entering or expanding in specific therapeutic markets.
Governance and leadership developments, including CEO transitions and changes in board roles, are disclosed via press releases and Form 8-K filings and form an important part of the company’s news record. For readers tracking MMSI, this news page aggregates updates on financial performance, product developments, acquisitions, regulatory milestones, and leadership changes, offering a centralized view of the company’s publicly reported activities.
Merit Medical (NASDAQ: MMSI) will release first quarter 2026 financial results after market close on Thursday, April 30, 2026. The company will hold an investor conference call the same day at 4:30 p.m. ET with a live webcast and slide deck available online.
Investors may pre-register for dial-in details; registration and webcast links will be posted at www.merit.com. Merit develops and distributes proprietary medical devices and employs about 7,600 people with over 800 sales and clinical support staff worldwide.
Merit Medical (NASDAQ: MMSI) acquired View Point Medical via merger, making View Point a Merit subsidiary effective April 1, 2026. The aggregate consideration is approximately $140 million including assumed liabilities, with $90 million paid at closing and two deferred $25 million payments.
Merit expects 2026 revenue contribution of $2M–$4M, 2027 contribution of $14M–$16M, near-term non‑GAAP EPS dilution of $0.05, and projects OneMark sales to grow ≥20% annually with ~70% non‑GAAP gross margins.
Medtronic entered a distribution agreement with Merit Medical Systems (NASDAQ: MMSI) to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation (BVNA) system.
ViaVerte is a minimally invasive, implant-free, physician-steerable BVNA system for chronic vertebrogenic lower-back pain; it will be available later in 2026 and expands Medtronic's pain interventions portfolio.
Merit Medical (NASDAQ: MMSI) announced the US commercial launch of the Resilience Through-the-Scope (TTS) Esophageal Stent on March 16, 2026. The stent is indicated for esophageal fistulas and malignant strictures and features proprietary anti-migration flanges, a single-handed deployment system, and unique sizes 14x50, 17x50, and 20x50 mm to address placement and migration challenges.
Merit Medical (NASDAQ: MMSI) reported fourth-quarter revenue of $393.9M (up 11%) and fiscal 2025 revenue of $1.516B (up 12%). GAAP EPS was $2.13 for 2025; non-GAAP EPS was $3.83 (up 11%). Free cash flow for 2025 was $215.7M (up 16%).
The company provided fiscal 2026 guidance of $1.61B–$1.63B revenue (+6%–8%) and non-GAAP EPS of $4.01–$4.15 (+5%–8%), and reported cash of $446.4M with total debt of $747.5M as of December 31, 2025.
Merit Medical (NASDAQ: MMSI) announced that the Board appointed F. Ann Millner as Chair of the Board effective January 5, 2026, following Fred P. Lampropoulos’ resignation as director and Chair on January 4, 2026. Lampropoulos will provide consulting services through March 31, 2026.
Merit reported preliminary unaudited Q4 2025 revenue of $389 million to $395 million, up approximately 10%–11% year‑over‑year. Preliminary constant currency revenue rose about 8%–10%, with a foreign exchange impact of $(4.4) million. Merit will release full Q4 and FY2025 results and fiscal 2026 guidance after market close on February 24, 2026 and hold a conference call at 4:30 p.m. ET.
Merit Medical (NASDAQ: MMSI) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Management will present a company overview on Tuesday, January 13, 2026 at 4:30 PM PT / 7:30 PM ET.
Martha G. Aronson, President and CEO, and Raul Parra, CFO, will deliver the presentation. A live audio webcast will be accessible via Merit’s investor relations "Events" page, and presentation materials will be posted to Merit’s investor relations "Investor Events and Presentations" page. A replay will be available on the site for approximately 90 days.
Merit Medical (NASDAQ: MMSI) said CMS has deferred consideration of its Transitional Pass-Through incremental payment application for the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) to the CY 2027 Outpatient Prospective Payment System, making Jan 1, 2027 the earliest possible effective date. Merit has withdrawn the TPT application and will begin full U.S. commercialization immediately. The company reiterated a 2025 U.S. revenue forecast of $2 million to $4 million for WRAPSODY CIE and cited 24-month efficacy results from its WRAPSODY WAVE Trial as a commercial differentiator. The device has FDA PMA (Dec 19, 2024), Health Canada approval (Apr 30, 2025), CE mark, and availability in Brazil.
Merit Medical (NASDAQ: MMSI) reported 24-month randomized AVF arm results from the WAVE trial showing the WRAPSODY Cell-Impermeable Endoprosthesis (CIE) had superior durability versus PTA.
Key results: target lesion primary patency (TLPP) 48.6% vs. 29.8% (p<0.0001) and access circuit primary patency (ACPP) 31.3% vs. 20.6% (p=0.003) at 24 months in 245 randomized hemodialysis patients across 43 centers. The device has US FDA premarket approval (Dec 19, 2024), Health Canada approval (Apr 30, 2025), CE mark, and availability in Brazil.
Merit Medical (NASDAQ: MMSI) reported 24-month efficacy from the non-randomized AVG cohort of the WAVE trial on Nov 3, 2025. The WRAPSODY CIE achieved a 6-month TLPP of 81.4% versus a 60% performance goal (p<0.0001). At 12 and 24 months TLPP was 60.2% and 41.7%, respectively; access circuit primary patency (ACPP) was 36.2% at 12 months and 25.7% at 24 months. The dataset includes 112 AVG patients across 43 centers; WRAPSODY holds FDA PMA (Dec 19, 2024) and Health Canada approval (Apr 30, 2025).